2023
Differences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19
Liu Y, Rajeevan H, Simonov M, Lee S, Wilson F, Desir G, Vinetz J, Yan X, Wang Z, Clark B, Possick J, Price C, Lutchmansingh D, Ortega H, Zaeh S, Gomez J, Cohn L, Gautam S, Chupp G. Differences in Mortality Among Patients With Asthma and COPD Hospitalized With COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3383-3390.e3. PMID: 37454926, PMCID: PMC10787810, DOI: 10.1016/j.jaip.2023.07.006.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseType 2 inflammationCOVID-19 severitySOFA scoreAirway diseaseNoneosinophilic asthmaSequential Organ Failure Assessment scoreOrgan Failure Assessment scoreSevere coronavirus disease 2019Higher SOFA scoreMedian SOFA scoreRetrospective cohort studyObstructive pulmonary diseaseOdds of mortalityLower SOFA scoresCells/μLCOVID-19 outcomesCoronavirus disease 2019Logistic regression analysisCOVID-19Clinical confoundersAsthma patientsCohort studyImmunological factorsClinical features
2022
The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
Sher L, Passalacqua G, Taillé C, Cohn L, Daizadeh N, Pandit-Abid N, Soler X, Khodzhayev A, Jacob-Nara J, Deniz Y, Rowe P, Nag A, Zhang Y. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma. Annals Of Allergy Asthma & Immunology 2022, 130: 298-304. PMID: 36509407, DOI: 10.1016/j.anai.2022.12.002.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsSevere asthmaActivity limitationsDose reductionAQLQ scoresDupilumab groupWeek 24Open-label extensionProportion of patientsType 2 inflammationHuman monoclonal antibodyQuality of lifeOral corticosteroidsOCS useInterleukin-4Long-term effectsAsthmaPatientsSymptomsMonoclonal antibodiesSleepReceptor componentsDupilumabDyspneaWeeks